Clinical Trial Results: Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating durvalumab, tremelimumab, and selumetinib in recurrent or stage IV non-small cell lung cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Selumetinib (selumetinib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-07-28